Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for delaying and treating erythroleukemia

A kind of technology of erythroleukemia and composition, applied in the field of compositions for delaying and treating erythroleukemia

Inactive Publication Date: 2018-10-16
GUIZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Sun et al. found that lycorine can play a significant anti-small cell lung cancer effect by blocking the Wnt / β-catenin signaling pathway; Roy et al. found that lycorine can inhibit autophagy by down-regulating HMGB1 and thereby inhibit multiple myeloma; Alkali exerts its anti-tumor activity in leukemia cells such as K562 and HL-60 by blocking the cell cycle and inducing apoptosis, but there are few reports on its therapeutic effect in erythroid leukemia by promoting erythroid differentiation and maturation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for delaying and treating erythroleukemia
  • Composition for delaying and treating erythroleukemia
  • Composition for delaying and treating erythroleukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] In order to make the objects and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0022] In vitro experiments:

[0023] 1. Lycorine (Lycorine) on the growth inhibition of HEL cells

[0024] The growth curve of HEL cells from 0 to 72h was detected by MTT method and drawn with different concentrations of lycorine (1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM). The results showed that as the concentration of lycorine increased, the growth rate of the cells gradually slowed down. Compared with the DMSO group, the growth rate of HEL cells in the 5, 10 and 20 μM lycorine treatment groups was significantly slowed down (p<0.01).

[0025] 2. Effect of Lycorine on HEL cell cycle

[0026] The effect of different concentrations of lycorine on ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses composition for delaying and treating erythroleukemia. The composition contains lycorine which can block the cell cycle of HEL (Human Erythroleukemia cell line) by inhibiting aJAK / STAT3 signal channel, induce the HEL to differentiate and mature into erythroid cells, and play a role in erythroleukemia resistance. The target of lycorine is XPO7, the effect of promoting erythroid differentiation is associated with downstream XPO7 of lycorine, and the composition is a potentially high-efficiency and low-toxicity clinical drug or lead compound.

Description

technical field [0001] The invention relates to the field of medicaments, in particular to a composition for delaying and treating erythroleukemia. Background technique [0002] Acute erythroid leukemia has no effective and specific treatment so far, and the same treatment strategies as other subtypes of AML are still used, such as chemotherapy and hematopoietic stem cell transplantation. Hematopoietic stem cell transplantation has a good therapeutic prospect, but due to various factors such as donor human leukocyte antigen (human leukocyte antigen, HLA) matching, inhibition risk assessment, post-transplant recurrence and various complications, and expensive medical expenses, etc. impact, making it difficult to promote clinically. Chemotherapy is still the main treatment. Traditional chemotherapy methods often use small-molecule drugs, which rely on cytotoxicity to directly damage the DNA of leukemia cells, block DNA repair, synthesis, and replication, hinder tumor cell mi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4745A61P35/02
CPCA61K31/4745A61P35/02
Inventor 雅科夫郝小江文敏李艳梅苑春茂顾玮杨珏林欣
Owner GUIZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com